Afuco™ Anti-SELP ADCC Therapeutic Antibody (Crizanlizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to SELP. Crizanlizumab is a human monoclonal antibody that can be potentially used in the treatment of Sickle Cell Disease (SCD).
Supplier | Creative Biolabs |
---|---|
Product # | AFC-TAB-015ML |
Pricing | Inquiry |
Host | Human |
Target | SELP |
Species Reactivity | Human |
Type | ADCC enhanced antibody |
Applications | ELISA, IHC, FC, IP, IF, FuncS |
Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |